Literature DB >> 10667887

Endocrine and neurological adverse effects of the therapeutic interferons.

T Vial1, G Choquet-Kastylevsky, C Liautard, J Descotes.   

Abstract

There is experimental evidence that the nervous central and the neuroendocrine systems can influence the immune system, which can in turn influence the brain activity. Endogenous cytokines are known to play a critical role in the pathophysiology of many diseases. The recently acquired experience on the adverse effects of therapeutic cytokines, particularly neurological and endocrine adverse effects, are further illustrative of these interferences. Interferons-alpha have been used in thousands of patients, so that the information accumulated with this group of closely related products is essential to delineate the potential and severity for non-immunological, but largely immune-mediated adverse effects to develop in patients treated with immuno-activating agents.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10667887     DOI: 10.1016/s0300-483x(99)00141-9

Source DB:  PubMed          Journal:  Toxicology        ISSN: 0300-483X            Impact factor:   4.221


  3 in total

1.  Bell's palsy and choreiform movements during peginterferon alpha and ribavirin therapy.

Authors:  Sener Barut; Hatice Karaer; Erol Oksuz; Asli Gündoğdu Eken; Ayse Nazli Basak
Journal:  World J Gastroenterol       Date:  2009-08-07       Impact factor: 5.742

2.  Multiple cranial neuropathies following zoledronic acid infusion: a relationship? Clinical features and pathogenic discussion concerning a case.

Authors:  S Deshayes; N Martin Silva; J Cogez; A Baldolli; S Fedrizzi; B Bienvenu; A Aouba
Journal:  Osteoporos Int       Date:  2016-03-15       Impact factor: 4.507

3.  Inhibition of euchromatic histone methyltransferase 1 and 2 sensitizes chronic myeloid leukemia cells to interferon treatment.

Authors:  Sheng Wei Loh; Wei Lun Ng; Kok Siong Yeo; Yat-Yuen Lim; Chee-Kwee Ea
Journal:  PLoS One       Date:  2014-07-31       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.